1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,866 | 0,872 | 13:23 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 50,92 | +0,55 % | Novonesis To Acquire Thailand Production Facility For Around $50 Mln | WASHINGTON (dpa-AFX) - Novozymes A/S, Novonesis (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B), a biotechnology company, on Wednesday announced an agreement to acquire a production facility... ► Artikel lesen | |
| GENMAB | 239,90 | +0,08 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,960 | -0,25 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| VERICEL | 28,400 | -4,70 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,350 | 0,00 % | Chancen dank Agrarwende: Bayer, Sumitomo und MustGrow Biologics | Die konventionelle Landwirtschaft muss umdenken: Chemische Pestizide sollen reduziert und durch biologische Alternativen ersetzt werden. Strenge Vorschriften wie die Farm-to-Fork-Strategie der Europäischen... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,380 | 0,00 % | Moleculin Biotech: Aktionäre genehmigen Ausgabe von Optionsscheinen, lehnen aber Namensänderung ab | ||
| SENSEI BIOTHERAPEUTICS | 29,220 | 0,00 % | Sensei Biotherapeutics, Inc. - 8-K, Current Report | ||
| BIOXCEL THERAPEUTICS | 0,908 | -0,44 % | BioXcel stellt vor FDA-Entscheidung Strategie für IGALMI-Markteinführung vor | ||
| REGENXBIO | 7,648 | -2,02 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| AKEBIA | 1,172 | +1,91 % | Leerink bestätigt Akebia-Rating nach regulatorischem Präzedenzfall | ||
| ZEVRA THERAPEUTICS | 8,600 | -2,49 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,100 | -1,92 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | ~ Delivered Record Annual Revenue with Full-Year Net PEDMARK- Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 13,730 | +7,64 % | Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating | ||
| CARTESIAN THERAPEUTICS | 5,000 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| NANOBIOTIX | 28,700 | +3,24 % | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results | Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,863 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.